The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd




- Aug 10, 2021
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM


- Dec 12, 2020
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma


- Dec 13, 2019
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM


- Dec 13, 2019
NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara


- Dec 11, 2019
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines


- Dec 6, 2019
NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dex or Daratumumab, Bortezomib, & Dex in NDMM Myeloma


- Dec 5, 2019
NCT03941860: Phase 3 - EAA171 - OPTIMUM - Addition of Ixazomib to Lenalidomide in Residual Myeloma


- Dec 4, 2019
NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM


- Dec 31, 2018
NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM


- Dec 20, 2018
NCT03562169: Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM Myeloma XII (ACCoRd)


- Dec 16, 2018
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)


- Dec 14, 2018
NCT03757221: Phase 2 - IFM 2018-02 - Ixazomib -Daratumumab Without Dex in Elderly RRMM (IDARA)


- Dec 8, 2018
NCT03683277: Phase 2: Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)


- Dec 6, 2018
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)


- Dec 3, 2018
NCT03720041: Phase 3 Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Elig. New MM (FiTNEss)


- Dec 14, 2017
Phase II HOVON 143 Study: Ixazomib, Dara and Low Dose Dex in Intermediate-Fit Patients NDMM


- Dec 8, 2017
NCT03012880: Phase 2 - Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab NDMM


- Dec 24, 2016
NCT01564537: Phase 3 - TOURMALINE-MM1 - Oral Ixazomib + Len/Dex Vs Placebo + Len/Dex RRMM


- Dec 16, 2016
NCT02765854: Phase 2: Ixazomib and Dex Vs Ixazomib, Dex and Lenalidomide, With NFKB2 Rearrangement


- Dec 9, 2016
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM


- Dec 3, 2015
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM


- Dec 17, 2014
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM


- Dec 14, 2014
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma


- Dec 13, 2014
NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT


- Dec 9, 2014
NCT02312258: Phase 3: TOURMALINE-MM4 - Oral Ixazomib Maintenance Therapy in NDMM-TIE


- Dec 11, 2013
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid


- Dec 6, 2013
NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM


- Dec 1, 2011
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib


- Dec 7, 2010
NCT01217957: Phase 1/2: A Study of Ixazomib in Combination With Lenalidomide and Low-Dex in NDMM